Vimta Labs (524394) Q2 25/26 earnings summary

Executive summary

• Achieved record quarterly sales revenue of INR 1,045 million in Q2 FY26, up 22.3% year-on-year, driven by pharmaceutical research/testing and food testing services.

• Maintained robust EBITDA and PAT margins above 19% for both the quarter and half-year.

• Clinical research division passed a successful WHO audit, reinforcing quality and compliance.

• Biologics contract research and development project is on schedule, with commercialization targeted for Q1 FY27.

• Unaudited financial results for Q2 and H1 FY2025-26 were reviewed and approved by the Board on November 3, 2025.

Financial highlights

• Q2 FY26 total income: INR 1,045 million, up 22.3% year-on-year; H1 FY26 total income: INR 2,038 million, up 26.6% year-on-year.

• Q2 FY26 EBITDA: INR 369 million (20.6% growth), margin at 35.3%; H1 FY26 EBITDA: INR 723 million (26.4% growth), margin at 35.5%.

• Q2 FY26 PAT: INR 199 million (17.1% growth), margin at 19.1%; H1 FY26 PAT: INR 388 million (25.5% growth), margin at 19%.

• Basic EPS: Q2 FY26 at INR 4.5; H1 FY26 at INR 8.7.

• Net debt-free balance sheet with cash and equivalents of INR 545 million.

Outlook and guidance

• No forward-looking numbers issued, but management remains confident in sustaining current run rate and targets an exit run rate of INR 500 crore for FY26 barring dramatic changes.

• Capacity expansions and investments in technology are in place to support future growth; no immediate capacity constraints anticipated.

• Emphasis on service innovation, risk management, and customer partnerships to drive future growth.